PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
74.78%
EBIT growth above 1.5x TRVN's 14.24%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
74.78%
Operating income growth above 1.5x TRVN's 14.24%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
64.85%
Positive net income growth while TRVN is negative. John Neff might see a big relative performance advantage.
64.71%
Positive EPS growth while TRVN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
64.71%
Positive diluted EPS growth while TRVN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-60.52%
Negative OCF growth while TRVN is at 37.31%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-60.52%
Negative FCF growth while TRVN is at 37.31%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
51.61%
10Y OCF/share CAGR in line with TRVN's 49.15%. Walter Schloss would see both as similarly efficient over the decade.
51.61%
Positive OCF/share growth while TRVN is negative. John Neff might see a comparative advantage in operational cash viability.
51.61%
Positive 3Y OCF/share CAGR while TRVN is negative. John Neff might see a big short-term edge in operational efficiency.
66.06%
Similar net income/share CAGR to TRVN's 60.68%. Walter Schloss would see parallel tailwinds or expansions for both firms.
66.06%
Positive 5Y CAGR while TRVN is negative. John Neff might view this as a strong mid-term relative advantage.
66.06%
Positive short-term CAGR while TRVN is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.06%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-5.28%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
11.50%
We have some new debt while TRVN reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-73.61%
We cut SG&A while TRVN invests at 10.57%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.